Phenotypic patterns of metabolic dysfunction‐associated steatotic liver disease in type 2 diabetes: The impact of insulin
European Journal of Clinical Investigation · 2025
DOI: 10.1111/eci.70050 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Clinical Investigation, 2025. Verfasst von Queralt Martín-Saladich und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical Molecular Imaging Research Group, Vall d'Hebron Research Institute (VHIR), Nuclear Medicine, Radiology and Cardiology Departments, Vall d'Heb…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Fatty Liver, Insulin, Insulin Resistance. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Agència de Gestió d'Ajuts Universitaris i de Recerca, Instituto de Salud Carlos III.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Metabolic dysfunction‐associated steatotic liver disease (MASLD) often leads to hepatic insulin resistance (IR), yet its link to liver‐specific insulin‐mediated glucose uptake (IGLU) in type 2 diabetes (T2D) remains unclear. We aimed to explore this MASLD‐T2D relationship, addressing organ‐specific IR for personalized management and risk prevention.
Methods
This cross‐sectional study included 41 T2D participants enrolled in a clinical trial (NCT02248311) undergoing biochemical analyses, anthropometric measurements and [ 18 F]FDG‐PET/CT imaging before and after hyperinsulinemic euglycemic clamp (HEC).
Findings
Two MASLD‐T2D phenotypes were identified according to their IGLU patterns, that is, with low (HepGluc[+], n = 21) and with high (HepGluc[−], n = 20) hepatic response to insulin. HepGluc[+] participants exhibited increased systemic IR (HOMA‐IR, p = .012), inflammation (interleukin 6, p = .005); alanine and aspartate aminotransferase ALT, AST ( p = .015 and p = .007); gamma‐glutamyl transferase GGT ( p = .019) and steatosis markers (liver volume, p = .006); NAFLD liver fat score, p = .0017; hepatic steatosis index, p = .02; fatty liver index, p = .008; liver stiffness measurements (LSM) ( p = .049). No statistical differences in serum‐based liver fibrosis scores were shown. To identify MASLD‐T2D phenotypes in a friendly manner, the MASLD‐T2D score based on support vector machines was developed using AST, ALT and GGT (AUC = .83), as well as with MASLD indices including LSM and NAFLD liver fat score (AUC = .90).
Implications
Two new MASLD‐T2D phenotypes have been identified, HepGluc[+] and HepGluc[−], according to IGLU patterns, with HepGluc[+] being more deleterious due to higher systemic IR, steatosis and inflammation. Phenotypes can be identified using a new function, the MASLD‐T2D score.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Molecular Imaging Research Group, Vall d'Hebron Research Institute (VHIR), Nuclear Medicine, Radiology and Cardiology Departments, Vall d'Hebron University Hospital (VHUH), Autonomous University Barcelona (UAB),…
- BCN MedTech, Information and Communication Technologies Department, Pompeu Fabra University, Barcelona, Spain.
- Diabetes and Metabolism Research Group, VHIR, Department of Endocrinology, VHUH, UAB, Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.
- Clinical Biochemistry Research Group, VHIR, Biochemical Core Facilities, VHUH, UAB, Barcelona, Spain.
- Catalan Institution for Research and Advanced Studies ICREA, Barcelona, Spain.
ORCID-Profile: Clara Ramirez-Serra, José Raul Herance
Förderung
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- Instituto de Salud Carlos III
Zitieren
APA
Martín-Saladich, Q., Simó, R., Ciudin, A., Baguña, J., Ramirez-Serra, C., Aguadé-Bruix, S., Roque, A., Pizzi, M. N., Cuéllar, H., Roson-Gradaille, N., González Ballester, M. A., Pericàs, J. M., & Herance, J. R. (2025). Phenotypic patterns of metabolic dysfunction‐associated steatotic liver disease in type 2 diabetes: The impact of insulin. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70050
Vancouver
Martín-Saladich Q, Simó R, Ciudin A, Baguña J, Ramirez-Serra C, Aguadé-Bruix S, et al. Phenotypic patterns of metabolic dysfunction‐associated steatotic liver disease in type 2 diabetes: The impact of insulin. European Journal of Clinical Investigation. 2025. doi:10.1111/eci.70050
BibTeX
@article{MartnSaladich2025,
author = {Martín-Saladich, Queralt and Simó, Rafael and Ciudin, Andreea and Baguña, Julia and Ramirez-Serra, Clara and Aguadé-Bruix, Santiago and Roque, Albert and Pizzi, Maria N and Cuéllar, Hug and Roson-Gradaille, Nuria and González Ballester, Miguel A and Pericàs, Juan M and Herance, José Raul},
title = {Phenotypic patterns of metabolic dysfunction‐associated steatotic liver disease in type 2 diabetes: The impact of insulin},
journal = {European Journal of Clinical Investigation},
year = {2025},
doi = {10.1111/eci.70050}
}
EUVIMED